Avalglucosidase alfa
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II
Conditions
Glycogen Storage Disease Type II, Pompe's Disease
Trial Timeline
May 7, 2025 → May 2, 2028
NCT ID
NCT06666413About Avalglucosidase alfa
Avalglucosidase alfa is a approved stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06666413. Target conditions include Glycogen Storage Disease Type II, Pompe's Disease.
What happened to similar drugs?
2 of 6 similar drugs in Glycogen Storage Disease Type II were approved
Approved (2) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06666413 | Approved | Recruiting |
| NCT04910776 | Phase 3 | Active |
| NCT02032524 | Phase 2 | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II